- Home
- ATRC
ATRC
AtriCure Inc.
as 07-01-2025 3:31pm EST
AtriCure Inc is an innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management and sells its products to medical centers through its direct sales force and distributors. Its product line includes Cryo, Soft Tissue Dissection, RF Ablation Pacing and Sensing, and others. Geographically, it generates a majority of its revenue from the United States. Cardiac ablation and left atrial appendage management (LAAM) products are used by physicians during open-heart and minimally invasive surgical procedures. Pain management solutions are used by physicians to freeze nerves during cardiothoracic or thoracic surgical procedures.
| Founded: | 2000 | Country: | United States |
| Employees: | N/A | City: | MASON |
| Market Cap: | 1.6B | IPO Year: | 2005 |
| Target Price: | $49.60 | AVG Volume (30 days): | 433.6K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 10 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.81 | EPS Growth: | N/A |
| 52 Week Low/High: | $20.20 - $43.11 | Next Earning Date: | 07-29-2025 |
| Revenue: | $480,076,000 | Revenue Growth: | 15.79% |
| Revenue Growth (this year): | 14.63% | Revenue Growth (next year): | 12.62% |
Stock Insider Trading Activity of AtriCure Inc. (ATRC)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Doraiswamy Vinayak | ATRC | Chief Scientific Officer | May 28 '25 | Sell | $33.44 | 2,500 | $83,600.00 | 73,550 |
Latest AtriCure Inc. News
ATRC Breaking Stock News: Dive into ATRC Ticker-Specific Updates for Smart Investing
Zacks
20 days ago
Are Medical Stocks Lagging Astellas Pharma (ALPMY) This Year?
Zacks
a month ago
Is Astellas Pharma (ALPMY) Stock Outpacing Its Medical Peers This Year?
Business Wire
a month ago
AtriCure to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference
Zacks
2 months ago
Does AtriCure (ATRC) Have the Potential to Rally 54.7% as Wall Street Analysts Expect?
Simply Wall St.
2 months ago
Shareholders in AtriCure (NASDAQ:ATRC) have lost 40%, as stock drops 11% this past week
MT Newswires
2 months ago
UBS Adjusts Price Target on AtriCure to $58 From $60, Maintains Buy Rating
Thomson Reuters StreetEvents
2 months ago
Q1 2025 AtriCure Inc Earnings Call
GuruFocus.com
2 months ago
AtriCure Inc (ATRC) Q1 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic ...
Compare ATRC vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "ATRC AtriCure Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.